The roles of M30 and M65 in the assessment of treatment response and prognosis in patients with non-small cell lung cancer, who receive neoadjuvant treatment

COŞKUN B. N., Dizdar O. s., Korkmaz S., ULUKAYA E., EVRENSEL T.

Współczesna Onkologia, cilt.23, sa.4, ss.208-213, 2019 (ESCI) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 23 Sayı: 4
  • Basım Tarihi: 2019
  • Doi Numarası: 10.5114/wo.2019.91539
  • Dergi Adı: Współczesna Onkologia
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus
  • Sayfa Sayıları: ss.208-213
  • Bursa Uludağ Üniversitesi Adresli: Evet

Özet

Aim of the study: To investigate the efficacy of evaluating prognosis and response to lung cancer treatment using M30 and M65 antigens, which are indicators of necrosis.